Publications for Kathleen Mulligan kathleen.mulligan@tu.edu
Gugliucci, A., Lustig, R. H., Caccavello, R., Erkin-Cakmak, A., Noworolski, S. M., Mulligan, K., . . . Schwarz, J. M. (2016). Short-term isocaloric fructose restriction lowers apoC-III levels and yields less atherogenic lipoprotein profiles in children with obesity and metabolic syndrome. Atherosclerosis, 253, 171-177. doi:10.1016/j.atherosclerosis.2016.06.048
Lustig, R. H., Mulligan, K., Noworolski, S. M., Tai, V. W., Wen, M. J., . . . Gugliucci, A., & Schwarz, J. M. (2016). Isocaloric fructose restriction and metabolic improvement in children with obesity and metabolic syndrome. Obesity, 24(2), 453-460. doi:10.1002/oby.21371
Schwarz, J. M., Noworolski, S. M., Wen, M. J., Jones, G. M., Sinclair, E., Velasco-Alin, M., Gugliucci, A., . . . Mulligan, K. (2015). Isocaloric fructose restriction for 10 days reduces hepatic de novo lipogenesis and liver fat in obese Latino and African American children [Supplemental material]. Endocrine Reviews, 36(2). This material can be found here.
Campos, G. M., Rabl, C., Havel, P. J., Rao, M., Schwarz, J. M., Schambelan, M., & Mulligan, K. (2014). Changes in post-prandial glucose and pancreatic hormones, and steady-state insulin and free fatty acids after gastric bypass surgery. Surgery for Obesity and Related Diseases, 10(1), 1-8. doi:10.1016/j.soard.2013.07.010
Jones, G. M., Sinclair, E., Pullinger, C., Caccavello, R., . . . Mulligan, K., Gugliucci, A., Schwarz, J. M. (2014). An immuno-affinity method to separate chylomicrons from VLDL and to ascertain the conversion of sugar to fat by de novo lipogenesis in human intestine. Diabetes, 63(Suppl. 1A), LB58. This material can be found here.
Rabl, C., Rao, C. M. N., Schwarz, J. M., Mulligan, K., Campos, G. M. (2014). Thermogenic changes after gastric bypass, adjustable gastric banding or diet alone. Surgery, 156(4), 806-813. doi:10.1016/j.surg.2014.06.070
Rao, M., Mulligan, K., Tai, V., Wen, M., Dyachenko, A., Weinberg, M., & Schambelan, M. (2010). Effects of insulin-like growth factor (IGF)-I/IGF-binding protein-3 treatment on glucose metabolism and fat distribution in human immunodeficiency virus-infected patients with abdominal obesity and insulin resistance. Journal of Clinical Endocrinology and Metabolism, 95(9), 4361-4366. PMCID:PMC2936071
Mulligan, K., Khatami, H., Schwarz, J. M., Sakkas, G. K., DePaoli, A. M., Tai, V. W., . . . Schambelan, M. (2009). The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. Journal of Clinical Endocrinology and Metabolism, 94(4):1137-1144. doi: 10.1210/jc.2008-1588 This material can be found here.